Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of March 2018. The report details the outcomes of the Company's Annual and Extraordinary General Meeting of Shareholders held on March 28, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural report regarding shareholder voting results and does not contain financial statements.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The document focuses solely on the approval of resolutions at the shareholder meeting.
Guidance, Outlook, and Management Commentary
Management reported that all proposed resolutions at the March 28, 2018 meeting were approved. Each matter voted upon received support from more than 95% of the votes participating in the meeting. The filing references a proxy statement furnished on February 22, 2018, for further details on the resolutions.
Investor Verification Checklist
- Verify the specific resolutions approved at the March 28, 2018 meeting by reviewing the proxy statement filed on February 22, 2018.
- Confirm the company name is BiondVax Pharmaceuticals Ltd., as the input metadata incorrectly listed Scinai Immunotherapeutics Ltd.
- Note that this filing contains no financial data; refer to Form 20-F for financial performance metrics.